http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 주제어 : Hydroxymethylglu -taryl-CoA reductase inhibitors (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
( Young Joon Hong ),( Myung Ho Jeong ),( Jang Ho Bae ),( Seok Kyu Oh ),( Seung Woon Rha ),( Seung Ho Hur ),( Sung Yun Lee ),( Sang Wook Kim ),( Kwang Soo Cha ),( In Ho Chae ),( Tae Hoon Ahn ),( Kee Si 대한내과학회 2017 The Korean Journal of Internal Medicine Vol.32 No.4
Background/Aims: We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients. Methods: Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month. Results: There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (.42.05 ± 32.73 mg/dL vs. .34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (.20.16 ± 54.49 mg/dL in 4 mg group and .24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (.0.13% ± 1.21% in 4 mg group and .0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively). Conclusions: Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.
-
Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
( Hyo Young Lee ),( Dae Won Jun ),( Hyun Jung Kim ),( Hyunwoo Oh ),( Waqar Khalid Saeed ),( Hyeongsik Ahn ),( Ramsey C. Cheung ),( Mindie H. Nguyen ) 대한내과학회 2019 The Korean Journal of Internal Medicine Vol.34 No.2
Background/Aims: A number of clinical trials reported varying effects of cho- lesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized con- trolled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of ev- idence was assessed using the grading of recommendations assessment, develop -ment and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion cri -teria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], -0.30; 95% confidence interval [CI], -0.57 to -0.03) but not hepatic steatosis in RCT (SMD, -0.1; 95% CI, -0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, -3.0; 95% CI, -6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
ScienceON
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
